John L. Krstenansky, Ph. D., M. B. A.
Professor and Director of Medicinal Chemistry
Department of Pharmacuetical Science and Research
Dr. Krstenansky received both a Bachelor of Science degree in Chemistry and a Bachelor of Arts degree in Philosophy from Loyola University in 1977. After completing his undergraduate studies, Dr. Krstenansky then began a Ph.D. program in Medicinal Chemistry at the University of Illinois at Chicago, which he completed in 1983. Following this, he completed a 2-year post-doctoral fellowship at the University of Arizona. Later in his career, Dr. Krstenansky earned a Master’s degree in Business Administration from Golden Gate University in 1997.
Dr. Krstenansky began his professional career in 1985 with Marion Merrell Dow Research Institute as a Senior Research Biochemist II, during which time he was named the 1990 Young Scientist of the Year by the Technical Societies Council of Cincinnati. In 1991 he moved to Syntex Discovery Research serving in a variety of capacities including Research Section Leader, Senior Staff Researcher, and Principal Scientist after the acquisition of Syntex by Roche. In 1997 Dr. Krstenansky joined EnzyMed, Inc. as Vice President for Research and Development. After EnzyMed was acquired by Albany Molecular Research, Inc., Dr. Krstenansky transitioned to Vice President of the EnzyMed Division. In 2001, he joined Consensus Pharmaceuticals, Inc., where he served as Vice President of Chemistry until 2003.
During his time in industry, Dr. Krstenansky also gained experience in teaching with appointments as Lecturer at both the University of California in Berkeley and the University of Iowa. Additionally, he served as Adjunct Faculty at the University of Iowa and the University of Cincinnati. In 2004, Dr. Krstenansky successfully transitioned to a full-time academic career at Loma Linda University, where he served until 2011, with a joint appointment as an Associate Professor of Medicinal Chemistry with the School of Pharmacy and an Associate Professor of Basic Sciences with the School of Medicine.
Dr. Krstenansky has participated in two entrepreneurial enterprises; as a managing partner in Straka Ventures, LLC since 2003, and as President and CEO of HubaTech, LLC since 2011. Furthermore, he has consulted for Roche Bioscience & AnaSpec, Inc., and been an ad hoc Reviewer on two study sections for the National Institutes of Health. He was the Chairman of the Biochemistry Discussion Group for the Cincinnati section of the American Chemical Society from 1989 to 1991 and the Medicinal Chemistry Discussion Group of the Santa Clara section of that same organization in 1997. He served as the Drug Discovery & Design Section representative for the 2011 AAPS National Biotech Conference planning committee. His expertise has been sought as a reviewer for a variety of industry journals, most recently as a member of the Editorial Advisory Board for the International Journal of Pharmaceutical and Biological Archives since 2010.
Dr. Krstenansky is a member of the American Association of Colleges of Pharmacy; the American Chemical Society, Divisions of Medicinal Chemistry and Organic Chemistry; the American Society of Pharmacognosy; the European Peptide Society, and the New York Academy of Sciences.
Dr. Krstenansky has received over 30 U. S. Patents, published over 80 articles, and been an invited speaker at over 20 national and international seminars.